Compare Citius Pharmaceuticals Inc (CTXR) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hyatt Hotels Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Hyatt Hotels Corporation trades at $161.94 (market cap $15.02B). The key difference: Hyatt Hotels Corporation is far larger — about 1102.8× Citius Pharmaceuticals Inc's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Hyatt Hotels Corporation for 148 Days on average.
| CTXR | H | |
|---|---|---|
Market Cap | $13.62M | $15.02B |
Volume | 132,438 | 842,340 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $202.09 |
52-Week Low | $0.48 | $135.42 |
Typical Hold Time | 17 Days | 148 Days |
Enterprise Value | $3.79M | $18.93B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Hyatt Hotels (H) trades at $161.94, up 3.05% today, near its pivot point of $159 with resistance at $162. The stock shows mixed technical signals but has consistently beaten earnings estimates in recent quarters. Revenue grew to $7.10B in 2025, though net income was negative. Analyst consensus is a Moderate Buy with a $197.77 price target, supported by recent strategic collaborations like the Delta Air Lines loyalty partnership announced September 9, 2026.
The outlook is cautiously optimistic given strong fee growth and expansion plans, but high valuation (P/E 196.83) and debt levels pose risks. Earnings momentum from Q3 2026 results, due October 29, 2026, will be critical for sustaining upside. Investors face volatility from regional economic weakness and project delays, requiring patience despite long-term growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
